CoChat

Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids

Open access
Schuster, Brooke, Junkin, Michael, Kashaf, Sara Saheb, Romero-Calvo, Isabel, Kirby, Kori, Matthews, Jonathan, Weber, Christopher R., Rzhetsky, Andrey, White, Kevin P., Tay, Savaş · 2020 · Nature Communications

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Three-dimensional (3D) cell culture technologies, such as organoids, are physiologically relevant models for basic and clinical applications. Automated microfluidics offers advantages in high-throughput and precision analysis of cells but is not yet compatible with organoids. Here, we present an automated, high-throughput, microfluidic 3D organoid culture and analysis system to facilitate preclinical research and personalized therapies. Our system provides combinatorial and dynamic drug treatments to hundreds of cultures and enables real-time analysis of organoids. We validate our system by performing individual, combinatorial, and sequential drug screens on human-derived pancreatic tumor organoids. We observe significant differences in the response of individual patient-based organoids to drug treatments and find that temporally-modified drug treatments can be more effective than constant-dose monotherapy or combination therapy in vitro. This integrated platform advances organoids models to screen and mirror real patient treatment courses with potential to facilitate treatment decisions for personalized therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-19058-4

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Automated microfluidic 3D cellular and organoid culture platform for dynamical drug perturbations. a A programmable membrane-valve-based microfluidic chip (multiplexer control device) provides automated stimulation profiles to various chambers of a separate 3D culture platform (b) to produce many parallel and dynamical culture experiments. b, c The 3D culture chamber platform contains 200 individual chambers that are compatible with temperature-sensitive gels (i.e., Matrigel), and an overlaying channel layer enables 20 independent fluidic conditions (scale bar 100 μm). The channel layer is reversibly clamped on top of the chamber layer to provide media and other chemical stimulation without leakage. c A cross-section of the two-layer multichambered PDMS-based 3D culture chamber device. d 30 chemical inputs and 30 outlets of the multiplexer control device (a) are preprogrammed to provide combinatorial and time-varying stimulations to the 3D culture chamber device (b). e, f Organoids or 3D cellular structures are continuously observed through time-lapse imaging for quantification; fluidic culture conditions can be changed on demand. The 3D culture chamber device can also be disassembled for cell harvesting and further cellular assays.
Fig. 1 Automated microfluidic 3D cellular and organoid culture platform for dynamical drug perturbations. a A programmable membrane-valve-based microfluidic chip (multiplexer control device) provides automated stimulation profiles to various chambers of a separate 3D culture platform (b) to produce many parallel and dynamical culture experiments. b, c The 3D culture chamber platform contains 200 individual chambers that are compatible with temperature-sensitive gels (i.e., Matrigel), and an overlaying channel layer enables 20 independent fluidic conditions (scale bar 100 μm). The channel layer is reversibly clamped on top of the chamber layer to provide media and other chemical stimulation without leakage. c A cross-section of the two-layer multichambered PDMS-based 3D culture chamber device. d 30 chemical inputs and 30 outlets of the multiplexer control device (a) are preprogrammed to provide combinatorial and time-varying stimulations to the 3D culture chamber device (b). e, f Organoids or 3D cellular structures are continuously observed through time-lapse imaging for quantification; fluidic culture conditions can be changed on demand. The 3D culture chamber device can also be disassembled for cell harvesting and further cellular assays.CC BY · PubMed Central
Fig. 2 Human tumor organoid culture and growth on microfluidic platform. a On-platform growth of organoids: three separate patient-derived pancreatic ductal adenocarcinoma (PDAC) organoids in Matrigel from single cells to formation of differentiated morphology of complex 3D structures (scale bar 100 μm). b Organoids from two patients were grown in parallel in a traditional 24-well plate and on our microfluidic platform (scale bar 100 μm). After mature organoid formation, organoids were harvested, H&E stained, and their morphologies compared and analyzed. In both platforms, organoids from patient 1 exhibited back-to-back glands with a high degree of nuclear atypia and pleomorphism with an accumulation of apoptotic luminal necrotic cells. Organoids from patient 4 demonstrated a well-differentiated morphology with simple spherical organoids and uniform nuclear and cytoplasmic features with little or no accumulation of necrotic luminal cells. c Organoid growth curves of PDAC organoid samples derived from three patients grown from single cells for 7 days on the platform. Each dot represents the cross-sectional area of an individual organoid. Patient 1 (blue), Patient 2 (red), Patient 3 (green). d Long-term culture, growth, and fluorescent staining of fixed PDAC organoids on the platform. Nuclei staining (DAPI) and F-actin (Phalloidin) are demonstrated (scale bar 100 μm). e Multiple Z image slices or stacks of a group of fixed and fluorescently stained organoids with DAPI and phalloidin (scale bar 100 μm).
Fig. 2 Human tumor organoid culture and growth on microfluidic platform. a On-platform growth of organoids: three separate patient-derived pancreatic ductal adenocarcinoma (PDAC) organoids in Matrigel from single cells to formation of differentiated morphology of complex 3D structures (scale bar 100 μm). b Organoids from two patients were grown in parallel in a traditional 24-well plate and on our microfluidic platform (scale bar 100 μm). After mature organoid formation, organoids were harvested, H&E stained, and their morphologies compared and analyzed. In both platforms, organoids from patient 1 exhibited back-to-back glands with a high degree of nuclear atypia and pleomorphism with an accumulation of apoptotic luminal necrotic cells. Organoids from patient 4 demonstrated a well-differentiated morphology with simple spherical organoids and uniform nuclear and cytoplasmic features with little or no accumulation of necrotic luminal cells. c Organoid growth curves of PDAC organoid samples derived from three patients grown from single cells for 7 days on the platform. Each dot represents the cross-sectional area of an individual organoid. Patient 1 (blue), Patient 2 (red), Patient 3 (green). d Long-term culture, growth, and fluorescent staining of fixed PDAC organoids on the platform. Nuclei staining (DAPI) and F-actin (Phalloidin) are demonstrated (scale bar 100 μm). e Multiple Z image slices or stacks of a group of fixed and fluorescently stained organoids with DAPI and phalloidin (scale bar 100 μm).CC BY · PubMed Central
Fig. 3 Combinatorial drug treatment of human tumor organoids on microfluidic platform. a On-platform drug treatment and stimulation with continuous fluorescence and phase imaging of organoids for the treatment duration. Each color represents a different drug formulation. Drug treatments on each channel can be changed on demand, creating time-varying drug treatments. Organoids can be analyzed for growth, morphology changes, or death. b Representative images (10×) of gemcitabine (100 nM) treated organoids for a 4-h drug pulse followed by normal growth media, continuous treatment of paclitaxel (10 nM) for 72-h, continuous treatment of gemcitabine (100 nM) for 72-h, a combination dose of gemcitabine (100 nM) + paclitaxel (10 nM) for 72-h, and negative and positive controls (staurosporine 10 mM). Caspase 3/7 reagent (green) used for apoptosis detection and propidium iodide (red) for dead cells along with phase contrast images (scale bar 100 μm). c Average caspase 3/7 signal over 72-h period of continuous single drug treatments for patient 1. d Average caspase 3/7 signal over 72-h period for a 4-h pulse of a single drug treatment followed by normal growth media for patient 1. e, f 72-h (e) and 4-h (f) drug treatments similarly examined for multiple known combinations of drugs. c–f All data presented as mean values ± SEM, n = 3, and normalized to positive control. Overall, combination chemotherapy treatment resulted in significantly increased apoptosis in tumor organoids compared to single drug treatments as expected. Source data for panels e, f are available.
Fig. 3 Combinatorial drug treatment of human tumor organoids on microfluidic platform. a On-platform drug treatment and stimulation with continuous fluorescence and phase imaging of organoids for the treatment duration. Each color represents a different drug formulation. Drug treatments on each channel can be changed on demand, creating time-varying drug treatments. Organoids can be analyzed for growth, morphology changes, or death. b Representative images (10×) of gemcitabine (100 nM) treated organoids for a 4-h drug pulse followed by normal growth media, continuous treatment of paclitaxel (10 nM) for 72-h, continuous treatment of gemcitabine (100 nM) for 72-h, a combination dose of gemcitabine (100 nM) + paclitaxel (10 nM) for 72-h, and negative and positive controls (staurosporine 10 mM). Caspase 3/7 reagent (green) used for apoptosis detection and propidium iodide (red) for dead cells along with phase contrast images (scale bar 100 μm). c Average caspase 3/7 signal over 72-h period of continuous single drug treatments for patient 1. d Average caspase 3/7 signal over 72-h period for a 4-h pulse of a single drug treatment followed by normal growth media for patient 1. e, f 72-h (e) and 4-h (f) drug treatments similarly examined for multiple known combinations of drugs. c–f All data presented as mean values ± SEM, n = 3, and normalized to positive control. Overall, combination chemotherapy treatment resulted in significantly increased apoptosis in tumor organoids compared to single drug treatments as expected. Source data for panels e, f are available.CC BY · PubMed Central
Fig. 4 Sequential and temporal drug treatment on the microfluidic platform reveals the efficacy of dynamic temporal drug treatment for personalized therapy. a Schematic of sequential drug delivery schedules of single drugs delivered temporally in pulses to recapitulate dynamic combination chemotherapy with the platform. Colors in each row represent a different drug formulation, which can be changed on-demand. b–h Comparison of the temporal delivery for five combination chemotherapies using average caspase 3/7 signal to detect apoptosis for patient 1. All data presented as mean values ± SEM, n = 3, and normalized to positive control. c–g Comparison of temporal delivery for each of the five combination chemotherapies to their 72-h and 4-h constant delivery counterparts (i.e., all drugs in the sequence at once). Details of the drugs used in each therapy regimen are shown below the graph and described in more detail in Table 1. Time course of each drug on the x-axis is to scale. h Comparison of all investigated therapies at the end of the 72-h drug treatment period (asterisk denotes significant differences from temporal treatment, two-way ANOVA, p values from left to right; FOLFIRINOX: 8.3E-07, 7E-07; FOLFIRI: 1.7E-06, 7E-07; FOLFOX: 0.03, 0.01; Gem+5-FU: 3.9E-05, 8.3E-05; Gem+Pac: 9.6E-10, 6.16E-06). Sequentially-administered combination therapy is more efficient in inducing tumor cell death. Source data for panels c–g are available.
Fig. 4 Sequential and temporal drug treatment on the microfluidic platform reveals the efficacy of dynamic temporal drug treatment for personalized therapy. a Schematic of sequential drug delivery schedules of single drugs delivered temporally in pulses to recapitulate dynamic combination chemotherapy with the platform. Colors in each row represent a different drug formulation, which can be changed on-demand. b–h Comparison of the temporal delivery for five combination chemotherapies using average caspase 3/7 signal to detect apoptosis for patient 1. All data presented as mean values ± SEM, n = 3, and normalized to positive control. c–g Comparison of temporal delivery for each of the five combination chemotherapies to their 72-h and 4-h constant delivery counterparts (i.e., all drugs in the sequence at once). Details of the drugs used in each therapy regimen are shown below the graph and described in more detail in Table 1. Time course of each drug on the x-axis is to scale. h Comparison of all investigated therapies at the end of the 72-h drug treatment period (asterisk denotes significant differences from temporal treatment, two-way ANOVA, p values from left to right; FOLFIRINOX: 8.3E-07, 7E-07; FOLFIRI: 1.7E-06, 7E-07; FOLFOX: 0.03, 0.01; Gem+5-FU: 3.9E-05, 8.3E-05; Gem+Pac: 9.6E-10, 6.16E-06). Sequentially-administered combination therapy is more efficient in inducing tumor cell death. Source data for panels c–g are available.CC BY · PubMed Central
Fig. 5 High-throughput drug testing of multiple patients on chip. a Heatmaps of organoids from three patients grown and stimulated in a simultaneous experiment. Cellular apoptosis (caspase 3/7) and death (propidium iodide) were recorded over the 72-h drug treatment period to assess drug sensitivity. b End-point analysis of average organoid cellular apoptosis and death for each patient and combination treatment group. All data presented as mean values ± SEM, n = 3, and normalized to positive control. Response comparisons between the different patients revealed distinct sensitivities to specific drug regimens across both independent cell viability assays. Source data for panels a, b are available.
Fig. 5 High-throughput drug testing of multiple patients on chip. a Heatmaps of organoids from three patients grown and stimulated in a simultaneous experiment. Cellular apoptosis (caspase 3/7) and death (propidium iodide) were recorded over the 72-h drug treatment period to assess drug sensitivity. b End-point analysis of average organoid cellular apoptosis and death for each patient and combination treatment group. All data presented as mean values ± SEM, n = 3, and normalized to positive control. Response comparisons between the different patients revealed distinct sensitivities to specific drug regimens across both independent cell viability assays. Source data for panels a, b are available.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 472

Metadata

Authors
Schuster, B., Junkin, M., Kashaf, S. S., Romero-Calvo, I., Kirby, K., Matthews, J., Weber, C. R., Rzhetsky, A., White, K. P., & Tay, S.
Affiliations
University of Chicago (US)
Corresponding author
Tay, Savaş
Venue
Nature Communications
Published
2020-10-19
Volume
11
Issue
1
Pages
5271-5271
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3092854160
Cited by
424
References
37
Citations by year
2026: 64 · 2025: 87 · 2024: 82 · 2023: 73 · 2022: 66 · 2021: 52
FWCI
14.99
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Autodesk
  • National Institutes of Health
  • National Institute of General Medical Sciences (R01GM127527)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK042086)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD007009)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Bio-sensing Technologies
Keywords
tumor organoids, high-throughput drug screening, combination therapy, pancreatic cancer, 3D cell culture, personalized treatment, patient-derived organoids
MeSH terms
Antineoplastic Agents, Automation, Drug Screening Assays, Antitumor, Humans, Organoids, Pancreatic Neoplasms, Cell Culture Techniques, Microfluidics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. https://app.cochat.ai/papers/10.1038/s41467-020-19058-4
The paper
Schuster, B., Junkin, M., Kashaf, S. S., Romero-Calvo, I., Kirby, K., Matthews, J., Weber, C. R., Rzhetsky, A., White, K. P., & Tay, S. (2020). Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nature Communications. https://doi.org/10.1038/s41467-020-19058-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.